As a reminder, view sessions and submit your evaluation form to claim your CME credits by December 31, 2021.
Selecting and Sequencing Targeted and Immunotherapy Regimens for RCC
How Will the Latest Evidence Impact Treatment Decisions for My Patients?
Sponsored by PeerView
TIP01: SWOG S1931 (PROBE): Phase III randomized trial of Immune checkpoint inhibitor (ICI) combination regimen with or without Cytoreductive Nephrectomy (CN) in Advanced Renal Cancer [NCT04510597]
Lead Author: Ulka Vaishampayan
TIP02: First-Line (1L) MK-1308A + Lenvatinib or Pembrolizumab + Belzutifan + Lenvatinib Versus Pembrolizumab + Lenvatinib for Clear Cell Renal Cell Carcinoma (ccRCC): A Randomized, Open-Label Phase 3 Study
Lead Author: Martin H. Voss
TIP03: Randomized, Open-Label, Phase 3 Study of Belzutifan Plus Lenvatinib Versus Cabozantinib in Patients With Advanced Renal Cell Carcinoma (RCC) After Anti–PD-1/PD-L1 Therapy
Lead Author: Robert Motzer
TIP04: Treatment of Advanced Renal Cell Carcinoma (RCC) After Progression on Systemic Therapy: Open-Label Phase 2 Study of Two Doses of the HIF-2α Inhibitor Belzutifan
Lead Author: Michael Atkins
TIP06: KEYNOTE-B61: An Open-Label Phase 2 Study of First-Line (1L) Pembrolizumab With Lenvatinib for Non–Clear Cell Renal Cell Carcinoma (nccRCC)
Lead Author: Chung-Han Lee
TIP07: Investigational Immune and Targeted Combination Therapies for Patients With Advanced Clear Cell Renal Cell Carcinoma (ccRCC): A Phase 1b/2 Umbrella Study
Lead Author: Laurence Albiges
TIP08: Optimal Treatment by Invoking biologic Clusters in Renal Cell Carcinoma (OPTIC RCC)
Lead Author: Yu-Wei Chen
TIP09: 89Zr-TLX250 for PET/CT Imaging of Clear Cell Kidney Cancer
Lead Author: Brian Shuch
TIP10: A randomized trial of radium-223 (Ra-223) dichloride and cabozantinib in patients (pts) with advanced renal cell carcinoma (RCC) with bone metastases (RADICAL / Alliance A031801)
Lead Author: Rana R. McKay
CTR11: First-line nivolumab plus ipilimumab (NIVO+IPI) versus sunitinib (SUN) in patients with long-term survival of ≥5 years in the CheckMate 214 trial
Lead Author: Nizar M. Tannir
CTR12: Outcomes with first-line nivolumab plus cabozantinib (NIVO+CABO) versus sunitinib (SUN) in patients with advanced renal cell carcinoma (aRCC) and treatment-related adverse event (TRAE) timing/management in CheckMate 9ER
Lead Author: Elizabeth R. Kessler
CTR13: A prospective randomized pilot trial of stereotactic body radiation therapy vs. radiofrequency ablation for the management of small renal masses
Lead Author: Ani Kapoor
CTR14: Characterization and Management of Adverse Reactions (ARs) in Patients With Advanced Renal Cell Carcinoma (aRCC) Receiving Lenvatinib + Pem- brolizumab (CLEAR Study)
Lead Author: Robert Motzer
CTR15: First results of 68Ga-EMP-100 PET for imaging c-MET expression in metastatic renal cell carcinoma
Lead Author: Lena Mittlmeier
N16: Anti-CAIX BBζ CAR4/8 T Cells Exhibit Superior Efficacy in a Clear Cell Renal Cell Carcinoma (ccRCC) Mouse Model
Lead Author: Yufei Wang
N17: Deconstructing the clear cell renal cell carcinoma using single nuclei multiomics
Lead Author: Michael P. Mariani
N18: Navigating multiomics in clear cell renal cell carcinoma-ccRCC: Network analyses on DNA methylation-5mC, DNA hydroxymethylation-5hmC, messenger RNA-mRNA, and microRNA-miRNA expression
Lead Author: Ze Zhang
N19: COVID-19 vaccination in patients with renal cell carcinoma receiving immune checkpoint inhibitors
Lead Author: Hannah Dzimitrowicz
N20: Radiation prior to combination-immunotherapy in patients with metastatic renal cell carcinoma (mRCC) and bone metastases
Lead Author: Hesham Yasin
N21: Adverse Events (AE) Management among Advanced Renal Cell Carcinoma (aRCC) Patients Receiving First-Line (1L) Axitinib+Checkpoint Inhibitor (CPI) Therapy
Leade Author: Yousef Zakharia
N22: Nivolumab plus cabozantinib (N+C) versus sunitinib (S) in patients with advanced renal cell carcinoma (aRCC) and bone metastasis: subgroup analysis of the Phase 3 CheckMate 9ER trial
Lead Author: Andrea Apolo
N23: Real-world clinical characteristics and treatment patterns of patients with advanced renal cell carcinoma treated with first-line avelumab + axitinib in the United States
Lead Author: Giovanni Zanotti
N24: Disease control rate (DCR) with tivozanib (TIVO) vs sorafenib (SOR) in relapsed/refractory (R/R) advanced RCC
Lead Author: Sumanta K. Pal
N25: Cost per survivor (CPS) and cost per life-month (CPLM) of nivolumab plus ipilimumab (NIVO+IPI) versus pembrolizumab plus axitinib (PEMBRO+AXI) for previously untreated advanced renal cell carcinoma (aRCC)
Lead Author: Stephen Huo
N26: Gene expression profiling (GEP) of non-clear cell renal cell carcinoma (nccRCC) identifies a unique spectrum of transcriptional signatures with potential clinical relevance
Lead Author: Pedro Barata
N27: Spectral Dual-Layer Detector CT: A New Independent Prognostic Tool in Metastatic Renal Cell Carcinoma
Lead Author: Aska Drljevic-Nielsen
N28: Direct Imaging Characteristics of Myeloid Derived Suppressor Cell (MDSC) Populations in Renal Cell Carcinoma Patients (RCC) by Ethnicity – An Exploratory Analysis
Lead Author: Arnab Basu
N29: Expression of Aberrant Splice Variants are Strongly Associated with Clinical Outcome in Clear Cell RCC
Lead Author: Andrew Chang
N30: Molecular profiling of metastatic renal cell carcinoma (mRCC) treated with ipilimumab-nivolumab (ipi-nivo)
Lead Author: Tian Zhang
N31: Evaluation of Provider Preferences in First-Line Metastatic Renal Cell Carcinoma
Lead Author: Priyanka V. Chablani
N32: Assessing human kidney cancer metabolism with intraoperative isotope tracing
Lead Author: Divya Bezwada
N33: Outcomes of Cytoreductive Nephrectomy Followed by Active Surveillance in Metastatic Renal Cell CarcinomaBAP1 Suppresses Tumor Growth Via Interferon Beta and ISGF3 in Clear Cell Renal Cell Carcinoma
Lead Author: Sari Khaleel
N34: BAP1 Suppresses Tumor Growth Via Interferon Beta and ISGF3 in Clear Cell Renal Cell Carcinoma
Lead Author: Lauren Langbein
N35: Machine learning predicts BAP1/PBRM1 from digital histology in clear cell Renal Cell Carcinoma: TRACERx Renal
Lead Author: Charlotte Spencer
N36: Adverse Radiologic and Pathologic Features Impact Survival Outcomes for Small Renal Masses Followng Nephrectomy
Lead Author: Sari Kahleel
E37: Characterization of the tumor immune microenvironment in clear cell renal cell carcinoma (ccRCC): prognostic and therapeutic implications of an M0-macrophage enriched subtype
Lead Author: Mark Farha
E38: Disease Free Survival (DFS) as a Predictor of Overall Survival (OS) in Localized RCC following First Nephrectomy
Lead Author: Naomi Haas
E39: Conditional survival and 5-year follow-up in CheckMate 214: first-line nivolumab plus ipilimumab (NIVO + IPI) versus sunitinib (SUN) in advanced renal cell carcinoma (aRCC)
Lead Author: Hans J. Hammers
E40: First-line nivolumab plus cabozantinib (NIVO+CABO) versus sunitinib (SUN) in patients with advanced renal cell carcinoma (aRCC) by prior nephrectomy status in the CheckMate 9ER trial
Lead Author: Camillo Porta
E41: A phase 3 trial of lenvatinib plus pembrolizumab (LEN+PEMBRO) versus sunitinib as a first-line treatment for patients with advanced renal cell carcinoma (aRCC): overall survival follow-up analysis (CLEAR study)
Lead Author: Toni K. Choueiri
E42: Characterizing the immune response in patients with renal cell carcinoma (RCC) following COVID-19 vaccination
Lead Author: Jasnoor Malhotra
E43: Nivolumab plus Cabozantinib in Patients with Non-Clear Cell Renal Cell Carcinoma: Results of a Phase 2 Trial
Lead Author: Chung-Han Lee
E44: Initial Management of Indeterminate Renal Masses in a Statewide Collaborative: a MUSIC-KIDNEY analysis
Lead Author: Mohit Butaney
E45: Documentation of Nephrometry Scores for cT1a Renal Masses Correlates with Avoidance of Radical Nephrectomy Across the MUSIC-KIDNEY Statewide QI Collaborative
Lead Author: Sara Perkins
E46: Building a roadmap for surveillance of renal masses: Results from MUSIC consensus panel
Lead Author: Amit Patel
LBA47: Molecular Dissection of Clear Cell Renal Cell Carcinoma Reveals Prognostic Significance of Epithelial-Mesenchymal Transition Gene Expression Signature
Lead Author: Srinivas Nallandhighal